Physician profile
Dolly Razdan
NPI 1699859512
$2,986.51
in general payments reported to CMS, 2019-2025
11 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.85 · 2021: $59.24 · 2022: $2,663 · 2023: $41.11 · 2024: $54.85 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $2,617.80 | 2019-2025 | Optune Gio |
| Bayer Healthcare Pharmaceuticals INC. | $114.48 | 2021-2025 | |
| Mevion_medical_systems_inc | $55.36 | 2022 | |
| Teleflex LLC | $40.31 | 2025 | Barrigel |
| Palette Life Sciences, INC. | $37.60 | 2022-2023 | |
| Progenics Pharmaceuticals, INC. | $32.73 | 2024 | |
| Novartis Pharmaceuticals Corporation | $24.21 | 2023 | Pluvicto |
| Boston Scientific Corporation | $20.19 | 2025 | Spaceoar System |
| Telix Pharmaceuticals | $18.53 | 2025 | Illuccix |
| Qfix | $13.03 | 2021 | |
| Merck Sharp & Dohme LLC | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dolly Razdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.